A retrospective cohort study suggested that colchicine prophylaxis at urate-lowering therapy initiation may lower cardiovascular event risk in patients with gout.
A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.
A new analysis found that acute anemia in patients who had a heart attack is associated with a higher risk of death or recurrent myocardial infarction at 30 days.
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
Acoramidis, an oral therapy, is now approved to reduce cardiovascular-related deaths and hospitalizations in adults with hereditary or wild-type ATTR-CM.
Plozasiran, a first-in-class RNA interference therapeutic, reduced triglycerides by 80% and lowered the risk of acute pancreatitis by 83% in patients with familial chylomicronemia syndrome, earning FDA...
In a study that assessed pericoronary adipose tissue (PCAT) density, researchers noted an association between higher PCAT density and greater coronary plaque burden and cardiovascular disease in people with...
A recent study found that non-dihydropyridine calcium channel blockers are associated with significantly less bradycardia during sinus rhythm compared with beta-blockers in patients with non-permanent...
This COVID-19 roundup includes coverage on the latest estimated number of adults with long COVID, WHO’s updated terminology for pathogens that transmit through the air, how COVID-19 vaccination reduces the...
